<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20864">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02835274</url>
  </required_header>
  <id_info>
    <org_study_id>A4150</org_study_id>
    <nct_id>NCT02835274</nct_id>
  </id_info>
  <brief_title>Study to Characterize Acute and Chronic Directional Aspects of Deep Brain Stimulation</brief_title>
  <acronym>DIRECT-DBS</acronym>
  <official_title>Directional Lead: Investigation of Rotational Current Steering, Ease of Use of Clinical Effects Map, and Therapeutic Outcomes of Deep Brain Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to characterize the programming effects of Boston Scientific
      Vercise™ PC System using the DBS Directional Lead for bilateral STN DBS for the treatment of
      Parkinson's disease in acute and chronic settings.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double Blind (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal set of stimulation parameters as measured by therapeutic window</measure>
    <time_frame>5 months post-implant</time_frame>
    <description>using predefined sets of programming parameters (combination of distribution of current per contact, amplitude, pulse width and frequency) to identify optimal (omni)directional stimulation parameters as measured by therapeutic window</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Optimal set of stimulation parameters as measured by therapeutic window</measure>
    <time_frame>3 months post-implant</time_frame>
    <description>using predefined sets of programming parameters (combination of distribution of current per contact, amplitude, pulse width and frequency) to identify optimal (omni)directional stimulation parameters as measured by therapeutic window</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Ring Mode Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>omni-directional stimulation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Unrestricted Mode Stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinician can use any type of stimulation that they deem best for the patient</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Deep Brain Stimulation (DBS) Boston Scientific VerciseTM PC System with Directional Lead</intervention_name>
    <arm_group_label>Ring Mode Stimulation</arm_group_label>
    <arm_group_label>Unrestricted Mode Stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of bilateral idiopathic PD with the presence of rigidity and at least one
             (1) of the following: resting tremor or bradykinesia.

          -  UPDRS III score of &gt;25 in the meds OFF condition

          -  Medication must improve PD symptoms by ≥30%, as measured by UPDRS subset III score

        Key Exclusion Criteria:

          -  Any significant psychiatric problems, including unrelated clinically significant
             depression as determined by the investigator

          -  Any current drug or alcohol abuse as determined by the investigator

          -  Any history of recurrent or unprovoked seizures

          -  Any significant medical condition that is likely to interfere with study procedures
             or likely to confound evaluation of study endpoints, including any terminal illness
             with survival &lt;12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens Volkmann, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Neurologische Klinik und Poliklinik, University of Wuerzburg, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ljubomir Manola, PhD</last_name>
    <phone>+32241 67219</phone>
    <email>Ljubomir.Manola@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Bowers</last_name>
    <phone>+16619494175</phone>
    <email>Diane.Bowers@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Neurologische Klinik und Poliklinik, University of Wuerzburg</name>
      <address>
        <city>Wurzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jens Volkmann, MD PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <lastchanged_date>July 20, 2016</lastchanged_date>
  <firstreceived_date>June 24, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>parkinson disease</keyword>
  <keyword>deep brain stimulation</keyword>
  <keyword>directional stimulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
